Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms

Pharmacogenetics

Volumn 6, Issue 4, 1996, Pages 279-290

  Krynetski, Eugene Y ^b   Tai, Hung Liang ^b   Yates, Charles R ^b   Fessing, Michael Y ^b   Loennechen, Thrina ^b   Schuetz, John D ^b   Relling, Mary V ^b   Evans, William E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

Azathioprine; Genetic polymorphism; Mercaptopurine; Thioguanine; Thiopurine S methyltransferase

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ANTINEOPLASTIC AGENT; AZATHIOPRINE; MERCAPTOPURINE; THIOGUANOSINE DERIVATIVE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNCLASSIFIED DRUG;

ALLELE; AUTOSOMAL RECESSIVE DISORDER; AUTOSOMAL RECESSIVE INHERITANCE; BLOOD TOXICITY; CLINICAL GENETICS; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME DEFICIENCY; ETHNIC GROUP; GENETIC POLYMORPHISM; HEMATOPOIETIC TISSUE; HUMAN; METHYLATION; MOLECULAR CLONING; MOLECULAR GENETICS; MUTANT; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW;

PIERINAE;

EID: 0029736709     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199608000-00001     Document Type: Review

References (60)

1. Allan PW, Bennett LL. 6-methylthioguanylic acid, a metabolite of 6-thioguanine. Biochem Pharmacol 1971: 20, 847.
2. Ames MM, Selassie CD, Woodson LC, Van Loon JA, Hansch C, Weinshilboum RM. Thiopurine methyltransferase: structure-activity relationships for benzoic acid inhibitors and thiophenol substrates. J Med Chem 1986: 29, 354-358.
3. Bennett LL, Brockman RW, Schnebli, HP, Chumlay S, Dixon GJ, Schabel FM, Dulmadge EA, Skipper H, Montgomery JA, Thomas HJ. Nature 1965: 205, 1276-1285.
4. Daly AK 1995.
5. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996: 6, 193-211.
6. Deininger M, Szumlanski CL, Otterness DM, Van Loon J, Ferber W, Weinshilboum RM. Purine substrates for human thiopurine methyltransferase. Biochem Pharmacol 1994: 48, 2135-2138.
7. Elion GB. The purine path to chemotherapy. Science 1989: 24, 441-447.
8. Evans WE, Relling MV. Mercaptopurine vs Thioguanine for the treatment of acute lymphoblastic leukemia. Leukemia Res 1994: 18, 811-814.
9. Evans WE, Homer M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991: 119, 985-989.
10. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993: 3, 45-50.
11. Hernandez JS, Van Loon JA, Otterness DM, Weinshilboum RM. Mouse thiopurine methyltransferase pharmacogenetics: correlation of immunoreactive protein and enzymatic activity. J Pharmacol Exp Ther 1990: 252, 568-573.
12. Hollander AAM, van Saase JLCM, Kootte AMM, van Dorp WT, van Bockel HJ, van Es LA, van der Woude FJ. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995: 345, 610-614.
13. Honchel R, Aksoy IA, Szumlanski C, Wood TC, Otterness DM, Wieben ED, Weinshilboum RM. Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA. Molec Pharmacol 1993: 43, 878-887.
14. Jacqz-Aigrain E, Bessa E, Medard Y, Mircheva Y, Vilmer E. Thiopurine methyltransferase activity in a French population: HPLC assay conditions and effects of drugs and inhibitors. Br J Clin Pharmacol 1994: 38, 1-8.
15. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995: 333, 958-63.
16. Jones CD, Smart C, Titus A, Blyden G, Dorvil M, Nwadike N. Thiopurine methyltransferase activity in a sample population of black subjects in Florida. Clin Pharmacol Ther 1993: 53, 348-353.
17. Kagan RM, Clarke S. Widespread occurrence of three sequence motifs in diverse S-adenosylmethionine-dependent methyltransferases suggests a common structure for these enzymes. Arch Biochem Biophys 1994: 310, 417-427.
18. Klemetsdal B, Tollefsen E, Loennechen T, Johnsen K, Utsi E, Gisholt K, Wist E, Aarbakke J. Interethnic difference in thiopurine methyltransferase activity. Clin Pharmacol Therap 1992: 51, 24-31.
19. Klemetsdal B, Straume B, Wist E, Aarbakke J. Identification of factors regulating thiopurine methyltransferase activity in a Norwegian population. Eur J Clin Pharmacol 1993: 44, 147-152.
20. Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE, Methylation of mercaptopurine, thioguanine and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol 1995a: 47, 1141-1147.
21. Krynetski EY, Schuetz JD, Galpin AJ, Pui C-H, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci (USA) 1995b: 92, 949-953.
22. Le Page GA. Incorporation of 6-thioguanine into nucleic acids. Cancer Res 1960: 20, 403-408.
23. Lee D, Szumlanski C, Houtman J, Honchel R, Rojas K, Overhauser J, Wieben ED, Weinshilboum RM. Thiopurine melhyltransferase pharmacogenetics: Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Met Disp 1995: 23, 398-405.
24. Lee EJ, Kalow W. Thiopurine S-methyltransferase activity in a Chinese population. Clin Pharmacol Ther 1993: 54, 28-33.
25. Lennard L, Singleton HJ. High-performance liquid Chromatographic assay of human red blood cell thiopurine methyltransferase activity. J Chrom 1994: 66, 125-133.
26. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukemia: a relationship between intracellular 6-mercaptopurine metabolism and neutropenia. Br J Clin Pharmacol 1983: 16, 359-63.
27. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989: 46, 149-154.
28. Lennard L, Lilleyman JS, Van Loon JA, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990: 336, 225-229.
29. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993: 68, 186-190.
30. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994: 343, 1188-1190.
31. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993: 341, 1151.
32. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Therap 1994: 55, 15-20.
33. McLeod HL, Krynetski EY, Wilimas JA, Evans WE. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics 1995a: 5, 281-286.
34. McLeod HL, Relling MV, Liu Q, Pui C-H, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995b: 85, 1897-1902.
35. Meyer UA. Genotype or phenotype: the definition of a pharmacogenetic polymorphism. Pharmacogenetics 1991: 1, 66-67.
36. Pacifici GM, Romiti P, Giuliani L, Rane A. Thiopurine methyltransferase in humans: development and tissue distribution. Develop Pharmacol Ther 1991: 17, 16-23.
37. Pazmino PA, Sladek SL, Weinshilboum RM. Thio S-methylation in uremia: Erythrocyte enzyme activities and plasma inhibitors. Clin Pharmacol Ther 1980: 28, 356-367.
38. Parks DA, Granger DN. Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol Scand (Suppl ) 1986: 548, 89-99.
39. Powell BL, Lyerly ES, Motsinger CP, Cruz JM, Chorley HM, Hurd DD, Cooper MR. Phase 1 study of continuous infusion 6-thioguanine in patients with acute leukemia. Leukemia 1995: 9, 770-773.
40. Remy CN. Metabolism of thiopyrimidines and thiopurines. J Biol Chem 1965: 238, 1078-1084.
41. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient, Lancet 1993: 341, 436.
42. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: Biochemical properties. liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992: 2, 148-159.
43. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, Spurr N, Lennard L, Wieben E, Weinshilboum R. Thiopurine methyltransferase pharmacogenetics: Human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996: 15, 17-30.
44. Tai HL, Krynetski EY, Krynetskaia NF, Yates CR, Evans WE. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996: 58, (to be inserted in page proof).
45. Tay BS, Lilley R, McMurray AW, Atkinson MR. Inhibition of phosphoribosyl pyrophosphate amidotransferase for Erlich ascites tumor cells by thiopurine nucleotides. Biochem Pharmacol 1969: 18, 936.
46. Tidd DM. Antipurines. Handbook Exp Pharmacol 1984: 72, 445-493.
47. Tidd DM, Patterson ARP. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974: 34, 738-746.
48. Tidd DM, Paterson ARP. Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974: 34, 733-737.
49. Tinel M, Berson A, Pessayre D, Letteron P, Cattoni MP, Horsmans Y, Larrey D. Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population. Br J Clin Pharmacol 1991: 32, 729-754.
50. Van Loon JA, Weinshilboum RM. Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem Genet 1982: 20, 637-58.
51. Van Loon JA, Weinshilboum RM. Thiopurine methyltransferase isozymes in human renal tissue. Drug Metab Dispos 1990: 18, 632-638.
52. Van Loon JA. Szumlanski CL, Weinshilboium RM. Human kidney thiopurine methyltransferase. Photoaffinity labelling with S-adenosyl-1-methionine. Biochem Pharmacol 1992: 44, 775-785.
53. Weinshilboum RM. Human pharmacogenetics of methyl conjugation, Fed Proc 1984: 43, 2303-2307.
54. Weinshilboum RM. Thiol S-methyltransferases I: Biochemistry II: Pharmacogenetics. In: Damani LA. ed. Sulphur-containing drugs and related organic compounds: Chemistry, biochemistry and toxicology. Harwood. Chichester, UK, 1989: Vol. 2. part A, 121-142, 144-156.
55. Weinshilboum RM. Methylation pharmacogenetics: thiopurine methyltransferase as a model system. Xenobiotica 1992: 22, 1055-1071.
56. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980: 32, 651-662.
57. Weinshilboum RM, Raymond FA, Pazmino PA. Human erylhrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties, Clin Chim Acta 1978: 85, 323-333.
58. Woodson LC, Ames MM, Selassic CD, Hansch C, Weinshilboum RM. Thiopurine methyltransferase: aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol Pharmacol 1985: 24, 471-478.
59. Woodson LC, Weinshilboum RM. Human kidney thiopurine methyltransferase: Purification and biochemical properties. Biochem Pharmacol 1983: 32, 819-826.
60. Woodson LC, Dunette JH, Weinshilboum RM. Pharmacogenelics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther 1982: 222, 174-181.